GNC Study Highlights Nutritional Gaps in GLP-1 Users' Diets
GLP-1s have become a popular weight loss solution for many consumers while also helping those with diabetes manage the disease.
But there may be some unintended consequences for those taking the drug, including overall poor diet quality along with nutrient deficiencies, a new study from GNC has revealed.
Entitled "Investigating Nutrient Intake During Use of Glucagon-like Peptide-1 Receptor Agonist: A Cross-Sectional Study," the study was conducted by senior researchers at GNC and included 69 GLP-1 users over a three-day period who completed surveys and a detailed food log.
RELATED: Store Brands Podcast: The Impact Of GLP-1s
Participant nutrient intake data was compared to the Dietary Reference Intakes (DRIs) using statistical analysis and demonstrated that participants did not meet vital nutrient intake through their diets and were significantly below recommended protein consumption.
Key findings of the study include:
- Poor diet quality overall: Participants did not meet USDA MyPlate servings for fruits, vegetables, grains, or dairy and demonstrated overconsumption of calories from fat and saturated fat.
- Low protein: While total caloric intake from protein was sufficient, the intake per body weight was below recommended levels.
- Nutrient deficiencies: Significant shortages were noted in the consumption of fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E.
GNC officials said the findings can help shape clinical practice guidance, supplement formulations, and education efforts to support the long-term success and safety of GLP-1 therapy, based on the population, not assumptions or speculation.
"We set out last year to develop a product tailored to the unique needs of GLP-1 users," said Dr. Brittany Johnson, PhD, RDN, senior manager, Scientific Affairs and principal investigator. "However, we quickly realized there simply wasn't enough evidence to inform a formula based on our scientific standards. That's why our team decided to start at the foundation and understand exactly what nutritional inadequacies exist in this population."
The clinical research, conducted according to academic standards, is the latest step in the brand's effort to support users in the weight management category. In 2024, GNC launched a GLP-1 support program with a selection of products designed to help semaglutide users manage common side effects and challenges associated with their treatment.
The full report is available online.
